DENVER, CO — November 10, 2025 — Leads & Copy —
Kraig Biocraft Laboratories (OTCQB: KBLB) is nearing the commercial delivery of high-performance recombinant spider silk after decades of scientific research and significant global investment, according to a report by 247marketnews.com.
Kraig Labs is preparing to ship spider silk fiber and fabric samples to partners in the fashion and performance textile industries. These shipments mark a turning point in biotechnology, according to 24/7 Market News.
Numerous governments, research institutions, and biotech startups have attempted to produce scalable spider silk, but they have failed due to production issues, high costs, and biological obstacles.
Past efforts include:
Nexia Biotechnologies (Canada): Spent over $110 million engineering goats to secrete spider silk proteins in milk but collapsed before achieving a viable scale.
DuPont (USA): Abandoned its bacterial expression project after investing millions due to insolubility problems.
BASF (USA): Citing insurmountable spinning challenges despite reportedly spending over $50 million on research and development, BASF also abandoned its spider silk project.
Bolt Threads (USA): After raising more than $400 million to produce “synthetic spider silk” through yeast fermentation, Bolt Threads pivoted to mycelium-based materials due to commercialization hurdles.
Spiber Inc. (Japan): Despite investing over $500 million in developing fermentation-based “Brewed Protein,” Spiber Inc. has yet to deliver material that matches the strength, elasticity, and economics of natural spider silk.
AMSilk (Germany): Backed by European venture funds and working with large consumer brands, AMSilk remains focused primarily on lab-scale quantities for niche applications.
China: Multiple state-backed research projects have explored transgenic silkworm and bacterial systems but remain pre-commercial.
Kraig Labs CEO Kim Thompson genetically engineered silkworms with spider silk DNA. By using PiggyBac gene transfer technology and developing proprietary gene-editing protocols, Kraig Labs created Dragon Silk™ and Monster Silk®, hybrid fibers that combine the strength and resilience of spider silk with the productivity of silkworm sericulture.
Kraig Labs operates multiple production facilities in Asia and is preparing to deliver its first fiber and fabric samples to three previously announced customers. These deliveries are expected to be the company’s first commercial sales.
Sample orders in the textile sector often require 10 to 250 kilograms of material for weaving, dyeing, and performance testing. These deliveries will serve as the first real-world validation of recombinant spider silk as a commercial product.
According to 24/7 Market News, these deliveries will officially mark the dawn of the commercial spider silk era, and likely establish Kraig Biocraft Laboratories as the benchmark for cost-effective production.
This moment separates speculation from execution, as Kraig Labs demonstrates that it can deliver real, high-performance spider silk at commercial scale in an economically sustainable way.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com.
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information, please visit: www.kraiglabs.com
Contact: 24/7 Market News, Editor@247marketnews.com
Source: Kraig Biocraft Laboratories, Inc.
Source: Kraig Biocraft Laboratories, Inc.
